X-82
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for X-82, covering 2018-06-27 to 2021-06-10. Get the full timeline:
Most recent: Clinical Trial Update: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]